PER-031-06已完成未知
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE II STUDY THAT COMPARES THE SAFETY OF MDX-010 (BMS-734016) ADMINISTERED WITH OR WITHOUT ORAL PROPHYLATIC BUDESONIDE (ENTOCORT TM EC) IN PATIENTS WITH MALIGNANT NON-EXTRACTABLE STAGE III OR IV PREVIOUSLY TREATED
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •a) Written informed consent, voluntarily signed and dated. It must be obtained before performing the procedures related to the protocol.
- •b) Able to comply with visits / procedures required by the protocol.
- •c) Life expectancy of at least 4 months.
- •d) ECOG 0-1 performance status score.
- •e) Histological or cytological diagnosis of non-resectable malignant melanoma of Stage III or IV.
- •f) Disease susceptible of measurement.
- •g) It must have been at least 4 weeks since the last chemotherapy, immunotherapy, hormonal therapy, radiotherapy or major surgery and the beginning of the protocol therapy.
- •h) The toxicity related to the previous therapy must have returned to ≤ grade 1, to the baseline or be considered irreversible.
- •i) Men and women 18 years and older. Women of childbearing age (WOCBP) should be using an adequate contraceptive method. The WOCBP must have a negative pregnancy test within 72 hours prior to the start of the study medication.
- •j) Values adequate for initial laboratory tests.
排除标准
- •a) WOCBPs that are not willing or able to use an acceptable method to avoid pregnancy during the entire study period and for at least 12 weeks after the study.
- •b) WOCBPs that use a prohibited method of contraception.
- •c) Women who are pregnant or breastfeeding.
- •d) Women with a positive pregnancy test at the time of enrollment or before administration of the study drug.
- •e) Sexually active fertile men who are unwilling or unable to use a barrier contraceptive or whose partners are WOCBP who do not use a method of birth control from the moment of enrollment and for 12 weeks after participation in the study.
- •f) Any other malignant disease that the patient has suffered for less than 5 years.
- •g) Ocular melanoma.
- •h) Central nervous system (CNS) metastasis untreated and active.
- •i) Autoimmune disease.
- •j) Any underlying medical condition, which makes the administration of the study drug dangerous or hinders the interpretation of adverse events.
- •k) Positive screening tests for HIV, HepB and HepC. If the positive results are not indicative of true active or chronic infection, the patient can be admitted after being discussed and agreed with the BMS Medical Monitor.
- •l) Therapies and / or prohibited medications.
- •m) Exposure to any of the products under investigation within 4 weeks prior to Day 1 of the treatment.
- •n) Pre-treatment with an anti-CLTA-4 antibody.
- •o) Use of any immunosuppressive treatment within 4 weeks prior to Day 1 of treatment.
- •p) Concomitant therapy with any of the following: IL-2, interferon or other anti-melanoma immunotherapy regimens that are not in the study; cytotoxic chemotherapy; immunosuppressive agents; other therapies in research or the chronic use of systemic corticosteroids.
- •q) Concomitant chemotherapy is prohibited.
- •r) Prisoners or patients who are required to be detained for the treatment of either a psychiatric or physical illness should not be enrolled in this study.
研究者
相似试验
招募中
不适用
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING DOSES OF THN391 IN HEALTHY SUBJECTSNeurological diseases10012272DementiaNL-OMON53329Therini Bio96
进行中（未招募）
1 期
A DOUBLE BLIND, PLACEBO-CONTROLLED, STUDY OF RT001 TREATMENT, FOR PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSISAmyotrophic Lateral SclerosisMedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-003962-38-NLRetrotope, Inc.44
进行中（未招募）
1 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSISAmyotrophic Lateral SclerosisMedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-003962-38-SERetrotope, Inc.44
进行中（未招募）
1 期
A Safety and Efficacy Study in Adult Patients with Moderate to Severe Atopic DermatitisEUCTR2018-001543-30-BERegeneron Pharmaceuticals, Inc.280
进行中（未招募）
1 期
A Safety and Efficacy Study in Adult Patients with Moderate to Severe Atopic DermatitisModerate to Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2018-001543-30-NLRegeneron Pharmaceuticals, Inc.280